South Korean biopharmaceutical company GC Pharma (KRX: 006280) stated on Friday its K-IFRS net income of KRW56.7bn for the year ended 31 December 2017.
This marks a growth of 13% in K-IFRS net income when compared to the prior year of 2016.
Revenues of KRW1.29tn were generated in 2017, a rise over revenues of KRW1.20tn in 2016, which was driven mainly by plasma products and vaccines sales.
Operating income of KRW90.3bn were recorded in 2017, up 15.1% from operating income of KRW78.5bn in 2016, primarily due to higher revenue from plasma and vaccine products and 1.3% lower SG&A expense rate.
(USD1=KRW1,08)
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development